Stockscreener 앱 받기
5.16
2.38%
0.12
시간 외 거래:
5.16
전일 마감가:
$5.04
열려 있는:
$5.02
하루 거래량:
2.28M
Relative Volume:
1.17
시가총액:
$1.05B
수익:
-
순이익/손실:
$-118.84M
주가수익비율:
-9.6557
EPS:
-0.5344
순현금흐름:
$-101.06M
1주 성능:
-3.01%
1개월 성능:
-9.79%
6개월 성능:
+46.18%
1년 성능:
+78.55%
1일 변동 폭
$4.88
$5.20
1주일 범위
$4.88
$5.51
52주 변동 폭
$1.89
$7.005
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.16 | 1.03B | 0 | -118.84M | -101.06M | -0.5344 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Savara’s MOLBREEVI BLA Receives FDA Priority Review - MSN
FDA to review Savara resubmitted Molbreevi BLA - MSN
Savara grants inducement equity awards to new employee - MSN
Weekly Earnings: Can Savara Inc withstand a market correctionGDP Growth & Proven Capital Preservation Tips - baoquankhu1.vn
FY2026 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat
Lifesci Capital Analysts Lift Earnings Estimates for Savara - MarketBeat
HC Wainwright Comments on Savara's Q1 Earnings (NASDAQ:SVRA) - MarketBeat
Savara says FDA review of MOLBREEVI to proceed without advisory committee - MSN
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
Langhorne, PA Biotech Eyes Mid-2026 Molbreevi Launch - streetwisereports.com
Growth Report: Will Savara Inc announce a stock splitForecast Cut & High Accuracy Swing Entry Alerts - baoquankhu1.vn
H.C. Wainwright Maintains Buy on Savara Inc. (SVRA) March 2026 - Meyka
H.C. Wainwright reiterates Savara stock rating, $10 target By Investing.com - Investing.com Australia
Savara receives FDA day 74 letter for autoimmune PAP drug By Investing.com - Investing.com Nigeria
Savara Inc. $SVRA Stake Cut by Farallon Capital Management LLC - MarketBeat
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
VR Adviser Increases Savara Inc. Holdings in Q4 2025News and Statistics - IndexBox
Savara Says FDA Review of MOLBREEVI to Proceed Without Advisory Committee - MyChesCo
SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan
SVRASavara Inc Latest Stock News & Market Updates - Stock Titan
Savara (NASDAQ:SVRA) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Decoding Savara Inc (SVRA): A Strategic SWOT Insight - GuruFocus
Savara receives FDA priority review for rare lung disease drug By Investing.com - Investing.com South Africa
Savara Inc. 2025 Annual Report: MOLBREEVI Clinical Progress, Business Strategy, and Key Risk Factors - Minichart
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Savara (SVRA) Advances with MOLBREEVI, Boosting Financial Positi - GuruFocus
Savara Signs Long-Term Lease for New Headquarters - TipRanks
Savara (NASDAQ: SVRA) details new Yardley headquarters lease terms - Stock Titan
SVRA: Regulatory progress and robust cash position set the stage for a potential 2026 launch - TradingView
Savara receives FDA priority review for rare lung disease drug - Investing.com
Savara : Corporate Presentation - marketscreener.com
Earnings Flash (SVRA) Savara Posts Q4 Loss $0.13 a Share, vs. FactSet Est of $0.12 Loss - marketscreener.com
Savara Q4 net loss widens as expenses rise - TradingView
Savara 10-K: $0M Revenue, $0.00 EPS; $118.8M Net Loss - TradingView
SVRA: Net loss increased to $118.8M in 2025 as MOLBREEVI advanced toward FDA review and commercialization - TradingView
MOLBREEVI strategy and FDA Priority Review drive Savara (NASDAQ: SVRA) - Stock Titan
BRIEF-Savara Q4 Net Income USD -32.236 Million - TradingView
Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update - The Joplin Globe
Rare lung disease drug MOLBREEVI nears key FDA decision on Aug. 22, 2026 - Stock Titan
Rosalind Advisors Inc. Has $14.28 Million Position in Savara Inc. $SVRA - MarketBeat
Savara (SVRA) Earnings Date and Reports 2026 - MarketBeat
Aug Shorts: Why is Savara Inc stock going down2026 Key Lessons & Intraday High Probability Alerts - baoquankhu1.vn
How FDA’s No-Advisory-Committee Path for MOLBREEVI Could Shape Savara (SVRA) Investors’ Outlook - simplywall.st
FY2030 Earnings Forecast for Savara Issued By HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: Savara (SVRA), Codexis (CDXS) and Diamedica Therapeutics (DMAC) - The Globe and Mail
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara (SVRA) Advances MOLBREEVI Application with FDA and EMA - GuruFocus
Savara Provides Regulatory Update on the MOLBREEVI* Development P - The National Law Review
Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Benzinga
Savara (SVRA) Is Down 8.0% After FDA Grants Priority Review To MOLBREEVIWhat's Changed - Yahoo Finance
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):